Asset profile
efimosfermin
Protein / enzyme therapeutic
Evidence outlook · lead readout
NCT04880031 · Nonalcoholic Steatohepatitis (NASH)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04880031: The study was randomized and double-blind with placebo control in its main comparative parts, enrolled 231 participants, and included an explicitly described open-label continuation for people who completed Part B. However, no primary endpoint results are posted, so whether the safety and tolerability comparisons were favorable cannot be assessed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
July 2028 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.